As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...